Lupkynis™ (voclosporin) – New drug approval
January 22, 2021 - Aurinia Pharmaceuticals announced the FDA approval of Lupkynis (voclosporin), in combination with a background immunosuppressive therapy regimen, for the treatment of adult patients with active lupus nephritis (LN).
Download PDF
